Back

Solution Seekers

Regular Users

Current states

While I use Dysport® fairly often, I am more likely to use it in complex patient cases

Desired states

Dysport® is my first choice as it lowers the level of symptom recurrence meaning patients come back for subsequent appointments in a better state, with less complications to manage.

Communication objectives

  1. Demonstrate the benefit of partnering with IPSEN to improve clinic efficiency

  2. Demonstrate Dysport® benefits and applicability across patient types

target

Messaging should be straight to the point, without complexity, with a focus on practical aspects of using Dysport®.

Communication objective associated: Demonstrate Dysport® benefits and applicability across patient types

  1. 1.Dysport® delivers reliable, patient-relevant outcomes across a broad range of adult spasticity cases, as shown in ULIS III and AboLiSh.

  2. Consistent results cycle after cycle real-world studies confirm sustained goal achievement with repeated Dysport® injections.

Key supportive study :

  • Upper limb ULIS III : Turner-Stokes L, et al. J Rehabil Med. 2021;53(1):jrm00133
  • Lower limb AboLish: Esquenazi A, et al. Arch Phys Med Rehabil. 2024

Key material:

  • CLM presentation

Digital material for follow up:

  • VAE reimbursement (to come)

Communication objective associated: Demonstrate Dysport® benefits and applicability across patient types

  1. The Dysport® duration of effect may be positively correlated with dose, which in turn correlates with a greater amount of active neurotoxin administered

  2. ULIS III real-world data show significantly longer intervals between Dysport® injections compared to other BoNT-As in upper limb spasticity, supporting fewer clinic visits and streamlined patient management.

  3. AboLiSh study shows a mean reinjection interval of approximately 18 weeks in ambulatory lower limb spasticity, enabling efficient scheduling and cumulative functional gains over treatment cycles.

Main key supportive study :

  • High amount of neurotoxin: . Field M, et al. Toxins. 2018;10:535
  • ULIS III : Turner-Stokes L et al., J Rehabil Med. 2021;53(1):jrm00133
  • AboLiSh : Esquenazi A et al., Arch Phys Med Rehabil. 2024.

Key material:

  • CLM presentation

Digital material for follow up:

  • Esquenazi webinar 
  • Jacinto reflection 
  • VAE to Ipsen Academy (to come)
  • VAE on duration of response (to come)

Communication objective associated: Demonstrate Dysport® benefits and applicability across patient types

  1. Dysport® contains the highest active neurotoxin content per licensed dose among BoNT-As, supporting effective treatment across a wide range of spasticity cases.
  2. Dysport® has a dose-response effect
  3. Flexible dosing allow clinicians to quickly tailor Dysport® treatment to each patient’s needs
  4. Recommended doses for upper / lower limb muscles

Main key supportive study :

  • Upper limb: Gracies J, et al. Muscle Nerve. 2018;57(2):245-254
  • Lower limb: Gracies J, et al. Neurology. 2017;89(22):2245-2253
  • Amount of neurotoxins: Field M, et al. Toxins. 2018;10:535

Key material:

  • CLM presentation
  • Dosing app

Digital material for follow up:

  • Dosing app guide (to come)

Communication objective associated: Demonstrate the benefit of partnering with IPSEN to improve clinic efficiency

  1. You have the power to deliver lasting control between treatment cycles and help prevent the early return of debilitating symptoms
  2. IXCELLENCE: the IPSEN Neuroscience HCP Training Program on the use of Dysport and spasticity management
  3. IXCELLENCE website to support you in your training journey with Dysport
  4. Dosing app to support you selecting the right dose at the right time

Key material

  • CLM presentation

Digital material for follow up

  • Invitation to (inter)national training